Patent Issued for Therapeutic compounds and methods (USPTO 11987577).
In: Gene Therapy Weekly, 2024-06-11, S. 4675-4675
serialPeriodical
Zugriff:
Actio Biosciences Inc. has been issued a patent for therapeutic compounds and methods. The patent focuses on the transient receptor potential vanilloid type 4 (TRPV4), a gene that encodes a calcium-permeable channel. TRPV4 is expressed in various tissues and has been implicated in respiratory diseases, joint diseases, pain, and bladder dysfunction. The patent provides compounds that can antagonize TRPV4 and includes claims for pharmaceutical compositions containing these compounds. This patent may be of interest to researchers studying genetic diseases and common diseases associated with TRPV4 activation. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Therapeutic compounds and methods (USPTO 11987577).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2024-06-11, S. 4675-4675 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Schlagwort: |
|
Sonstiges: |
|